Moderna stock surged 33.3% after positive news on mRNA vaccines and new EU contract.

From Nasdaq: 2025-01-25 15:11:20

Moderna’s stock (MRNA) surged 33.3% this week, marking a significant gain after a 90% downtrend. The company received positive news with mentions of mRNA vaccines at Project Stargate and a new contract with the European Union. Moderna’s stock is up 21.6% this week, and artificial intelligence developments could revolutionize the mRNA vaccine industry. Despite stagnating sales, the company is working on vaccines for various diseases like RSV and the flu. The European Union contract for COVID-19 vaccinations is expected to boost revenue growth for Moderna.

Investors are considering whether to buy Moderna stock, which is currently at a market cap of $15 billion. With $9 billion in cash and potential growth in AI development, Moderna presents an interesting opportunity for a turnaround bet. The company’s stock could benefit from AI advancements and is trading at a low price, making it an attractive long-term option for investors. However, it’s important to note that Moderna did not make the list of the 10 best stocks to buy now, according to the Motley Fool Stock Advisor analyst team.



Read more at Nasdaq: Why Moderna Stock Jumped Over 20% This Week